ZA97858B - Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant. - Google Patents

Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant.

Info

Publication number
ZA97858B
ZA97858B ZA9700858A ZA97858A ZA97858B ZA 97858 B ZA97858 B ZA 97858B ZA 9700858 A ZA9700858 A ZA 9700858A ZA 97858 A ZA97858 A ZA 97858A ZA 97858 B ZA97858 B ZA 97858B
Authority
ZA
South Africa
Prior art keywords
granulocyte
adjuvant
stimulating factor
colony stimulating
macrophage colony
Prior art date
Application number
ZA9700858A
Other languages
English (en)
Inventor
Elke Jager
Alexander Knuth
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of ZA97858B publication Critical patent/ZA97858B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9700858A 1996-02-09 1997-02-03 Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant. ZA97858B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/598,909 US6096313A (en) 1996-02-09 1996-02-09 Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant

Publications (1)

Publication Number Publication Date
ZA97858B true ZA97858B (en) 1997-08-04

Family

ID=24397438

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9700858A ZA97858B (en) 1996-02-09 1997-02-03 Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant.

Country Status (12)

Country Link
US (1) US6096313A (de)
EP (1) EP0932411B1 (de)
JP (1) JP2000506518A (de)
AT (1) ATE243525T1 (de)
AU (1) AU723147B2 (de)
CA (1) CA2244867C (de)
DE (1) DE69723092T2 (de)
DK (1) DK0932411T3 (de)
ES (1) ES2196305T3 (de)
PT (1) PT932411E (de)
WO (1) WO1997028816A1 (de)
ZA (1) ZA97858B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7611721B1 (en) 1999-05-13 2009-11-03 Wyeth Holdings Corporation Adjuvant combination formulations
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
TW581709B (en) 1999-10-22 2004-04-01 Asahi Kasei Corp Heat-resistant microporous film
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
SG143058A1 (en) * 2000-08-11 2008-06-27 Favrille Inc Method and composition for altering a t cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
PE20020530A1 (es) * 2000-11-10 2002-06-18 Wyeth Corp Formulaciones de combinacion adyuvante
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
KR100668573B1 (ko) * 2002-10-18 2007-01-16 아사히 카세이 메디칼 가부시키가이샤 친수성 미다공막
ES2661082T3 (es) 2003-01-30 2018-03-27 Survac Aps Péptidos derivados de survivina y uso de los mismos
EP2087904B1 (de) 2003-11-19 2013-08-28 Survac ApS Verwendung von Bcl-XL Protein abgeleiteten Peptide bei Krebspatienten
WO2005087260A1 (en) * 2004-03-04 2005-09-22 Corixa Corporation Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
JP2008528643A (ja) 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
EP1760089B1 (de) * 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
GB2432722A (en) * 2005-11-25 2007-05-30 Seiko Epson Corp Electrochemical cell and method of manufacture
GB2432721B (en) * 2005-11-25 2011-06-22 Seiko Epson Corp Electrochemical cell structure and method of fabrication
GB2432723B (en) * 2005-11-25 2010-12-08 Seiko Epson Corp Electrochemical cell and method of manufacture
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
BRPI0814140A2 (pt) * 2007-07-27 2017-03-28 Immatics Biotechnologies Gmbh composição de peptídeos associados a tumor e vacina anticâncer relacionada
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
NO2280721T3 (de) 2008-04-17 2018-04-14
CN102056622B (zh) * 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2817418A1 (en) 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2492279A1 (de) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige
EP2546358A1 (de) 2011-07-15 2013-01-16 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Reagenzien zur effizienten Steuerung des HIV-Fortschritts
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
CA2850245C (en) 2011-10-17 2020-04-28 Herlev Hospital Pd-l1 based immunotherapy
WO2013060328A1 (en) 2011-10-26 2013-05-02 Herlev Hospital Ikb based immunotherapy
EP2606897A1 (de) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Zusammensetzungen für die Behandlung von Krankheiten, die von eingehüllten Viren verursacht werden
EP2617434A1 (de) 2012-01-20 2013-07-24 Laboratorios Del. Dr. Esteve, S.A. HIV-1-Integrase-defiziente Immunogene und Verfahren zum Beladen von dentritischen Zellen mit besagten Immunogenen
EP2620446A1 (de) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogene zur HIV-Impfung
EP2698377A1 (de) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Verbessertes schnelles Immunogene Auswahlverfahren für HIV gp120 Varianten
EP2703482A1 (de) 2012-09-04 2014-03-05 Laboratorios Del. Dr. Esteve, S.A. VSV-HIV-Virenpartikel mit Mangel an Umkehrtranskriptasefunktionalität und therapeutische Anwendungen davon
EP2886126B1 (de) 2013-12-23 2017-06-07 Exchange Imaging Technologies GmbH An CD44-bindende Peptide konjugierte Nanopartikel
SI3193917T1 (sl) 2014-09-17 2022-02-28 Io Biotech Aps Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce
IL257940B (en) 2015-09-16 2022-08-01 Herlev Hospital Vaccines that include the CC motif. Chemokine 22 or fragments thereof
EP3147364A1 (de) 2015-09-28 2017-03-29 Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS) Antivirale wirkstoffe mit einem oligonukleotid-lipid-konjugat-bildenden g-quadruplex
EP3468585A2 (de) 2016-06-10 2019-04-17 IO Biotech APS Calr- und jak2-impfstoffzusammensetzungen
EP3275462A1 (de) 2016-07-27 2018-01-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Virusähnliche partikel mit hochdichter beschichtung zur herstellung von neutralisierenden antikörpern
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
US20220226459A1 (en) 2019-05-22 2022-07-21 Aelix Therapeutics, S.L. Dosage regimens for vaccines
EP4058058A1 (de) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosierungsschema für impfstoffe
WO2022017895A1 (en) 2020-07-21 2022-01-27 Rhovac Aps Treatment of residual disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TNSN93075A1 (fr) * 1992-07-08 1994-03-17 Schering Corp Utilisation de gm-csf comme adjuvant pour vaccin
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
WO1998006746A2 (en) * 1996-08-16 1998-02-19 The Johns Hopkins University School Of Medicine Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same

Also Published As

Publication number Publication date
EP0932411A4 (de) 2001-09-26
EP0932411A1 (de) 1999-08-04
ES2196305T3 (es) 2003-12-16
CA2244867A1 (en) 1997-08-14
WO1997028816A1 (en) 1997-08-14
AU1755297A (en) 1997-08-28
CA2244867C (en) 2003-09-09
DE69723092T2 (de) 2003-12-18
EP0932411B1 (de) 2003-06-25
ATE243525T1 (de) 2003-07-15
JP2000506518A (ja) 2000-05-30
DE69723092D1 (de) 2003-07-31
DK0932411T3 (da) 2003-08-18
US6096313A (en) 2000-08-01
AU723147B2 (en) 2000-08-17
PT932411E (pt) 2003-11-28

Similar Documents

Publication Publication Date Title
PT932411E (pt) Composicoes contendo moleculas imunogenicas e factor estimulante de colonias de macrofagos- granulocitos como adjuvante
MY132705A (en) Novel compounds with analgesic effect
CA2274074A1 (en) Novel compounds with analgesic effect
MY122383A (en) Cyclic boroproline compounds
MX9603560A (es) Composiciones de prostaglandinas estables en almacenamiento.
BG102600A (en) Carbamoyloxy derivatives of mutilin and their use as bactericides
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
PL319833A1 (en) Compounds and composition for carrying active media
CA2291065A1 (en) Raf kinase inhibitors
NZ215779A (en) Substituted benzonaphthalene derivatives and pharmaceutical and cosmetic preparations
GR3007385T3 (de)
AU690588B2 (en) Novel pyrazine carboxamide derivatives, their production and their use in medicaments
AU669122B2 (en) New pyrazine derivatives, their preparation and their use
AU2096897A (en) Serum cholesterol lowering agent
GB9425730D0 (en) Compounds
IL150125A0 (en) Novel compounds
NZ511445A (en) Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
SE9402880D0 (sv) New peptide derivatives
CA2095352A1 (en) Compositions containing psyllium
DE3567211D1 (en) (pyrrol-1-yl)-phenyl-dihydropyridazinones, their preparation and use
AU617036B2 (en) Phenylhydrazones, the manufacture thereof and therapeutic and cosmetic compositions prepared therefrom
AU4299696A (en) Use of the hepatocyte growth factor to induce proliferation and differentiation of hemopoietic cells
ES550742A0 (es) Un procedimiento para la preparacion de una octahidroindo- lizina
NZ217281A (en) Phenyl ether derivatives and pharmaceutical compositions
EP0371733A3 (de) Dopamin-beta-hydroxylase-Inhibitoren